Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells

The promise of PARP-inhibitors(PARPis) in the management of epithelial ovarian cancer(EOC) is tempered by the fact that approximately 50% of patients with homologous recombination (HR)-proficient tumors do not respond well to these agents. Combination of PARPis with agents that inhibit HR may repres...

Full description

Bibliographic Details
Main Authors: Choi, Young Eun, Battelli, Chiara, Watson, Jacqueline, Liu, Joyce, Curtis, Jennifer, Morse, Alexander N., Matulonis, Ursula A., Chowdhury, Dipanjan, Konstantinopoulos, Panagiotis A.
Format: Online
Language:English
Published: Impact Journals LLC 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058036/